405171-06-4

Basic information

• Product Name: 2(1H)-Quinolinone, 4-chloro-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-
• CAS NO: 405171-06-4
• Molecular Formula: C27H23ClN4O2
• Molecular Weight: 470.958
• Mol File: 405171-06-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2(1H)-Quinolinone, 4-chloro-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinolinone, 4-chloro-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(405171-06-4)
• EPA Substance Registry System: 2(1H)-Quinolinone, 4-chloro-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(405171-06-4)

Safety Data

• Hazardous Substances Data: 405171-06-4(Hazardous Substances Data)

Upstream product

• 405171-01-9 4-hydroxy-3-(5-morpholin-4-ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one 

Downstream Products

• 405171-07-5 4-[(2-methoxyethyl)amino]-3-(5-morpholin-4-ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one 

Relevant articles and documents

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Quinolinone derivatives

Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.